<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05090566</url>
  </required_header>
  <id_info>
    <org_study_id>C1071004</org_study_id>
    <secondary_id>Umbrella Study</secondary_id>
    <secondary_id>MAGNETISMM-4</secondary_id>
    <secondary_id>2021-003885-11</secondary_id>
    <nct_id>NCT05090566</nct_id>
  </id_info>
  <brief_title>MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma</brief_title>
  <official_title>A PHASE 1B/2, OPEN LABEL UMBRELLA STUDY OF ELRANATAMAB (PF-06863135), A B-CELL MATURATION ANTIGEN (BCMA) CD3 BISPECIFIC ANTIBODY, IN COMBINATION WITH OTHER ANTI-CANCER TREATMENTS IN PARTICIPANTS WITH MULTIPLE MYELOMA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the Recommended Phase 2 Dose and clinical benefit&#xD;
      of elranatamab in combination with other anti-cancer therapies in participants with multiple&#xD;
      myeloma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 28, 2021</start_date>
  <completion_date type="Anticipated">August 17, 2026</completion_date>
  <primary_completion_date type="Anticipated">November 24, 2025</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sub-Study A Phase 1: Dose Limiting Toxicity</measure>
    <time_frame>35 days</time_frame>
    <description>Number of participants with Dose Limiting Toxicity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sub-Study A Phase 2: Objective Response Rate</measure>
    <time_frame>assessed every 4 weeks (for approximately 2 years)</time_frame>
    <description>Objective response rate (IMWG response criteria)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sub-Study A Phase 1: Objective Response Rate</measure>
    <time_frame>assessed every 4 weeks (for approximately 2 years)</time_frame>
    <description>Objective response rate (IMWG response criteria)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sub-Study A Phase 1 and Phase 2: Cumulative Complete Response Rate</measure>
    <time_frame>assessed every 4 weeks (for approximately 2 years)</time_frame>
    <description>Cumulative complete response rate (IMWG response criteria)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sub-Study A Phase 1 and Phase 2: Time to Response</measure>
    <time_frame>assessed every 4 weeks (for approximately 2 years)</time_frame>
    <description>Time to response (IMWG criteria)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sub-Study A Phase 1 and 2: Duration of Response</measure>
    <time_frame>assessed every 4 weeks (for approximately 2 years)</time_frame>
    <description>Duration of response (IMWG response criteria)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sub-Study A Phase 1 and Phase 2: Duration of Cumulative Complete Response</measure>
    <time_frame>assessed every 4 weeks (for approximately 2 years)</time_frame>
    <description>Duration of cumulative complete response (IMWG response criteria)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sub-Study A Phase 1 and Phase 2: Progression Free Survival</measure>
    <time_frame>assessed every 4 weeks (for approximately 2 years)</time_frame>
    <description>Progression free survival (IMWG response criteria)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sub-Study A Phase 1 and Phase 2: Overall Survival</measure>
    <time_frame>assessed for approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sub-Study A Phase 1 and Phase 2: Minimal Residual Disease Negativity Rate</measure>
    <time_frame>assessed approximately every 12 months (for approximately 2 years)</time_frame>
    <description>Minimal residual disease negativity rate (IMWG response criteria)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sub-Study A Phase 1 and Phase 2: Frequency of Treatment-Emergent Adverse Events</measure>
    <time_frame>assessed for approximately 2 years</time_frame>
    <description>Type and severity per NCI CTCAE v5 (CRS and ICANS assessed per ASTCT criteria)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sub-Study A Phase 1 and Phase 2: Frequency of Laboratory Abnormalities</measure>
    <time_frame>assessed every cycle (each cycle approximately 28 days)</time_frame>
    <description>Type and severity per NCI CTCAE v5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sub-Study A Phase 1 and Phase 2: Immunogenicity of elranatamab in combination with nirogacestat</measure>
    <time_frame>assessed approximately every 1 to 3 cycles (each cycle approximately 28 days)</time_frame>
    <description>Anti-drug antibodies and neutralizing antibodies against elranatamab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sub-Study A Phase 1 and Phase 2: Concentrations of elranatamab and/or nirogacestat</measure>
    <time_frame>assessed approximately every 1 to 3 cycles (each cycle approximately 28 days)</time_frame>
    <description>Pre-dose and post-dose concentrations of elranatamab; pre-dose concentrations of nirogacestat</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sub-Study A Phase 1: Maximum Observed Concentration (Cmax) for elranatamab</measure>
    <time_frame>assessed after first elranatamab dose (approximately 3-7 days)</time_frame>
    <description>Cmax for elranatamab administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sub-Study A Phase 1: Time to Maximum Concentration (Tmax) for elranatamab</measure>
    <time_frame>assessed after first elranatamab dose (approximately 3-7 days)</time_frame>
    <description>Tmax for elranatamab administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sub-Study A Phase 1: Area Under the Concentration versus Time Curve from Time 0 to the Last Measurable Concentration (AUClast) for elranatamab</measure>
    <time_frame>assessed after first elranatamab dose (approximately 3-7 days)</time_frame>
    <description>AUClast for elranatamab administration</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Sub-study A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BCMA-CD3 bispecific antibody + gamma secretase inhibitor</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elranatamab + Nirogacestat</intervention_name>
    <description>BCMA-CD3 bispecific antibody + gamma secretase inhibitor</description>
    <arm_group_label>Sub-study A</arm_group_label>
    <other_name>PF-06863135</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Relapsed/refractory multiple myeloma with at least 3 prior lines of therapy&#xD;
&#xD;
          -  Refractory to at least one IMiD, one proteasome inhibitor, and one anti-CD38 antibody&#xD;
&#xD;
          -  Measurable disease defined by at least one of the following:&#xD;
&#xD;
               1. Serum M-protein &gt;/= 0.5 g/dL by SPEP&#xD;
&#xD;
               2. Urinary M-protein excretion &gt;/= 200 mg/24 hours by UPEP&#xD;
&#xD;
               3. Serum immunoglobulin FLC &gt;/= 10 mg/dL (&gt;/= 100 mg/L) AND abnormal serum&#xD;
                  immunoglobulin kappa to lambda FLC ratio&#xD;
&#xD;
          -  ECOG performance status 0 -1&#xD;
&#xD;
          -  Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade &lt;/= 1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active plasma cell leukemia&#xD;
&#xD;
          -  Amyloidosis&#xD;
&#xD;
          -  Stem cell transplant with 12 weeks prior to enrollment, or active GVHD&#xD;
&#xD;
          -  POEMS syndrome&#xD;
&#xD;
          -  Any active uncontrolled bacterial, fungal, or viral infection&#xD;
&#xD;
          -  Impaired cardiovascular function or clinically significant cardiovascular diseases&#xD;
             within 6 months prior to enrollment&#xD;
&#xD;
          -  Previous treatment with an anti-BCMA bispecific antibody&#xD;
&#xD;
          -  Previous administration with an investigational drug within 30 days or 5 half-lives&#xD;
             preceding the first dose of study treatment (whichever is longer)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sylvester Comprehensive Cancer Center - The Lennar Foundation Medical Center</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33146</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sylvester Comprehensive Cancer Center- Deerfield Beach</name>
      <address>
        <city>Deerfield Beach</city>
        <state>Florida</state>
        <zip>33442</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UHealth Tower</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=C1071004</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 8, 2021</study_first_submitted>
  <study_first_submitted_qc>October 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PF-06863135, Multiple Myeloma, BCMA, elranatamab, bispecific antibody, MagnetisMM-4</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
    <ipd_url>https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

